KYMR Q3 2025 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-26.1% YoY

Gross Profit

-$71M-2580.7% margin

Operating Income

-$93M-3347.4% margin

Net Income

-$82M-2973.0% margin

EPS (Diluted)

$-0.94

QoQ Revenue Growth

-75.9%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$156M

Stockholders' Equity

$946M

Cash & Equivalents

$113M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$4M	-26.1%
Gross Profit	-$71M	$4M	-2006.7%
Operating Income	-$93M	-$72M	-28.3%
Net Income	-$82M	-$62M	-31.5%